ARTICLE | Clinical News
Obinutuzumab regulatory update
November 19, 2012 8:00 AM UTC
The European Commission granted Orphan Drug designation for obinutuzumab from Roche to treat chronic lymphocytic leukemia (CLL). The humanized mAb against CD20 is in Phase III testing for CLL, non-Ho...